<DOC>
	<DOCNO>NCT01006681</DOCNO>
	<brief_summary>The spread Influenza H1N1 prompt development vaccine virus . Immunocompromised patient increase risk develop complication Influenza H1N1 . The efficacy safety H1N1 vaccination evaluate population patient .</brief_summary>
	<brief_title>Vaccination Against Influenza H1N1 Rheumatic Diseases</brief_title>
	<detailed_description>100 patient Rheumatoid Arthritis ( RA ) , 50 patient Systemic Lupus Erythematosus ( SLE ) , 50 patient spondyloarthropathies ( Psoriatic arthritis ( PsA ) Ankylosing Spondylitis ( AS ) 200 healthy subject participate study . All subject vaccinate Focetria ( Novartis ) evaluate day vaccination 4 week later . The evaluation include : Efficacy vaccine : Blood drawn day 0 4 week later test presence antibody A/California17/2009/H1N1 hemagglutination inhibition test . Safety vaccine : - Records adverse event - Assessment disease activity : RA - Disease activity score ( DAS 28 ) , SLE - SLEDAI , PsA - DAS 28 PASI , AS- BASDAI , ESR , CRP</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Patients suffer : Rheumatoid Arthritis , Systemic Lupus Erythematosus , Ankylosing Spondylitis , Psoriatic Arthritis Able firm inform consent Aged 1865 Candidates receive vaccination H1N1 , accord recommendation Ministry Health Allergy egg Known allergy seasonal influenza vaccine Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>rheumatoid</keyword>
	<keyword>SLE</keyword>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>Ankylosing</keyword>
	<keyword>Influenza H1N1</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Vaccination H1N1 rheumatic disease</keyword>
</DOC>